BRIEF published on 12/09/2025 at 14:55, 1 month 20 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 1 month 20 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 1 month 20 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 2 months 18 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 2 months 18 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 2 months 24 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 2 months 24 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 3 months 19 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 3 months 19 days ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 4 months 12 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
Published on 01/30/2026 at 00:00, 16 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 1 hour 16 minutes ago PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/29/2026 at 18:45, 5 hours 31 minutes ago Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 6 hours 16 minutes ago PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units
Published on 01/29/2026 at 17:00, 7 hours 16 minutes ago Sparta Reports on Delay in Filing Annual Financial Statements
Published on 01/30/2026 at 00:07, 8 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appointment of independent non-executive director
Published on 01/29/2026 at 21:02, 3 hours 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 21:01, 3 hours 15 minutes ago Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 01/29/2026 at 20:59, 3 hours 16 minutes ago Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited
Published on 01/29/2026 at 20:57, 3 hours 18 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 01/29/2026 at 18:00, 6 hours 16 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 6 hours 31 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 6 hours 31 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 10:07, 14 hours 8 minutes ago Deezer confirms demonetization of up to 85% of AI-music streams due to fraud and moves to sell AI-detection tech
